Open AccessRepaglinide and metformin (diabetic treatments) enhance sexual efficiency
Author(s) -
Karrar Salih Mahdi,
Farah Safaa Abdulhussein Alwan,
Iman Jabber Hasen,
Mustafa Jawad Al-Imari
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.6307
Subject(s) - repaglinide , metformin , alloxan , dose , medicine , diabetes mellitus , endocrinology , testosterone (patch) , type 2 diabetes , spermatogenesis , sperm , sperm motility , pharmacology , andrology
Diabetes mellitus type 2 (DMT2) is one of the modern societies’ highest public health threats. For a while, it was believed that DM had no impact on male reproductive function; however, new research has cast doubt on that assumption. To find out whether repaglinide and metformin may improve sperm motility and testosterone levels in diabetic and non-diabetic albino rats, researchers in this study used these two drugs to treat diabetes. Methods: Alloxan injections at three dosages of 120 mg/kg intraperitoneal produced type 2 diabetes in male rats. Experimental rats were classified into two main groups. The first group included four subgroups of male rats treated with alloxan (DM inducer). Each subgroup contained seven rats “1. Control without any treatment (positive control), 2. treated by 500 mg/kg metformin, 3. treated by 4 mg/kg repaglinide, and 4. treated by 500 mg/kg metformin and 4 mg/kg repaglinide”. The second group also includes four subgroups but without alloxan treated. Each subgroup has seven rats; all are categorized in the same initial group and receive identical treatment dosages.